So much has happened in the immuno-oncology industry since we spoke to Peter at last year’s IO Frontiers World in Miami. However, the balance between opportunities and challenges remain and we still need discussion and collaboration to
With every new regulatory opportunity come great challenges…
Peter Olagunju is the Senior Technical Director at Bluebird Bio and has a wealth of CMC and supply chain experience across a range of advanced therapies. In this video, Peter gives insight into:
- The opportunities brought by accelerated clinical development
- Tension points in CMC as a result of expedited time frames
- Improving the shelf life of autologous therapy starting materials
These discussions will continue at IO Frontiers World this January 22-25 in Miami; the most senior partnering event for the immuno-oncology industry. Find out more about the meeting here or go straight to the agenda.